WASHINGTON - The outcry over informed consent following the death of a clinical trial volunteer at the University of Pennsylvania's Institute for Human Gene Therapy (IHGT) could have widespread impact on biomedical research extending well beyond gene therapy.

Congress, regulatory agencies, and ethics watchdogs have been prompted to launch or accelerate investigations into the adequacy of patient protections in the wake of allegations that IHGT investigators violated informed consent regulations.